The Financial Review reports that GenesisCare is raising $1 billion as it prepares to enter the US healthcare market via the acquisition of 21st Century Oncology. In Australia, GenesisCare has grown from six cancer treatment centres in 2009 to 37 centres today, while it entered the UK in 2015 and Spain in 2016 via acquisitions.
The alliance between Noxopharm and GenesisCare is a vote of confidence in NOX66, in my view. It is clear that GenesisCare has been treating late-stage patients with NOX66 for some time and that the alliance would not have been consummated unless results had been good.
It remains to be seen how many patients receive combination treatment with NOX66 per year, but the prospect of significant pain reduction together with longer survival means that demand should be high.
GenesisCare Implications
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |